Q-omics provides the consensus-scored TMEM130 profile across patient tissues and cancer cell-line models. TMEM130 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TMEM130 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TMEM130 RNA expression shows 23,837 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where TMEM130 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM130 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM130 survival associations across molecular data types. TMEM130 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM130 RNA expression–survival associations across cancer types. High TMEM130 expression shows favorable associations in SKCM, ACC, LUAD, CESC, THCA and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TMEM130 RNA expression.
This table summarizes TMEM130 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM130. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM130 shows lower tumor expression in COAD, KICH, LUSC and LUAD and higher tumor expression in HNSC and THCA. The HNSC box plot shows higher TMEM130 RNA expression in tumor versus normal tissue (log2 FC = +0.538, t-test p < 0.001).
This table shows molecular features associated with TMEM130 in patient tissues and cancer cell lines. In patient samples, TMEM130 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM130 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and CNS.
